Impaired hematopoiesis affects apheresis and CAR T‐cell product composition and treatment response

Key Points

• This research examines how impaired hematopoiesis influences T-cell production and treatment outcomes in patients receiving CAR T-cell therapy.
• Evaluated the timing of leukapheresis in relation to intensive treatments.
• Analyzed T-cell products for yield and quality.
• Assessed treatment responses based on T-cell characteristics.
• Early leukapheresis led to higher T-cell yields and improved product quality.
• Patients receiving optimized T-cell products demonstrated better therapeutic responses.
• Impaired hematopoiesis negatively impacted both T-cell yield and treatment efficacy.